During the shutdown 3 areas will be taken up for upgradation as per CGMP norms, which are expected to be completed in 4-6 weeks.
1. Beta Lactum block:- All the three areas for beta lactum block i.e. Power for suspension, tablets section and capsule area including dispensing area and warehouse for API are being taken up for upgradation as per regulated market.
2. Non Beta Powder for suspension block - complete revamp of non beta pfs area with increased capacity and dedicated AHU with dehumidification as per regulated market requirements.
3. ORS manufacturing are:- This area is being converted to install additional auto plant of liquid fabrication for 2.5 KL capacity along with auto mono block liquid filling/ sealing machine with auto cartoner.
The upgradation would not only enable MBL to prepare for regulated market but also provide next level of growth in terms of goog volume business with better margins, the company said.
Medicamen Biotech Ltd is currently trading at Rs462.95 up by Rs2.55 or 0.55% from its previous closing of Rs460.40 on the BSE.